| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.04 [0.74, 1.47] | | < 1 | | 84% | 2 studies (2/-) | 40.2 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.04 [0.49, 2.23] | | < 1 | | 97% | 2 studies (2/-) | 45.5 % | some concern | not evaluable | moderate | important | - |
| DOR | 2.27 [1.44, 3.57] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.70 [1.18, 2.46] | | > 1 | | 63% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.72 [0.17, 17.14] | | < 1 | | 71% | 2 studies (2/-) | 32.3 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.89 [0.39, 2.06] | | < 1 | | 91% | 2 studies (2/-) | 60.3 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.68 [0.70, 4.01] | | < 1 | | 71% | 2 studies (2/-) | 12.3 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.28 [0.49, 3.35] | | < 1 | | 93% | 2 studies (2/-) | 30.7 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.16 [0.31, 4.35] | | < 1 | | 97% | 2 studies (2/-) | 41.1 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.04 [0.23, 4.78] | | < 1 | | 96% | 2 studies (2/-) | 47.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.96 [0.27, 3.35] | | < 1 | | 87% | 2 studies (2/-) | 52.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.94 [0.34, 2.58] | | < 1 | | 95% | 2 studies (2/-) | 55.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.68 [0.14, 3.40] | | < 1 | | 38% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.43 [0.09, 22.89] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.82 [0.47, 1.44] | | < 1 | | 78% | 2 studies (2/-) | 75.3 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.74 [0.33, 1.63] | | < 1 | | 0% | 2 studies (2/-) | 77.5 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 8.08 [0.43, 153.53] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.71 [0.06, 7.89] | | < 1 | | 0% | 2 studies (2/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.96 [0.69, 5.58] | | < 1 | | 27% | 2 studies (2/-) | 10.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 6.05 [0.30, 121.16] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.12 [0.62, 2.02] | | < 1 | | 0% | 2 studies (2/-) | 35.0 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 2.04 [0.04, 103.19] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.25 [0.67, 2.32] | | < 1 | | 21% | 2 studies (2/-) | 23.9 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 2.66 [1.10, 6.46] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.00 [0.06, 16.05] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 4.02 [0.18, 89.44] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.46 [0.72, 2.93] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.36 [0.25, 7.43] | | < 1 | | 68% | 2 studies (2/-) | 36.3 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.87 [0.68, 1.12] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 2.01 [0.37, 11.06] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 4.04 [0.45, 36.31] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.68 [0.40, 7.07] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.01 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.89 [0.51, 1.56] | | < 1 | | 47% | 2 studies (2/-) | 65.9 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 1.06 [0.28, 4.08] | | < 1 | | 20% | 2 studies (2/-) | 46.6 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 0.81 [0.16, 4.23] | | < 1 | | 0% | 1 study (1/-) | 59.6 % | NA | not evaluable | | non important | - |
| Agranulocytosis (AE grade 3-4) | 4.09 [0.14, 122.39] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 2.04 [0.04, 103.19] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.68 [0.47, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.13 [0.01, 2.20] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.63 [0.23, 1.74] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.25 [0.03, 2.02] | | < 1 | | 0% | 1 study (1/-) | 90.1 % | NA | not evaluable | | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.51 [0.02, 11.32] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 0.34 [0.02, 6.78] | | < 1 | | 0% | 1 study (1/-) | 75.8 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.20 [0.01, 3.72] | | < 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.34 [0.02, 6.78] | | < 1 | | 0% | 1 study (1/-) | 75.8 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.02 [0.34, 3.02] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Diabetes mellitus AE (grade 3-4) | 0.51 [0.02, 11.32] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.15 [0.59, 2.26] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 2.04 [0.13, 32.81] | | < 1 | | 0% | 1 study (1/-) | 30.9 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 4.09 [0.14, 122.39] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 2.04 [0.04, 103.19] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.18 [0.04, 0.76] | | < 1 | | 0% | 1 study (1/-) | 99.0 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 2.04 [0.13, 32.81] | | < 1 | | 0% | 1 study (1/-) | 30.9 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.78 [0.41, 1.48] | | < 1 | | 0% | 1 study (1/-) | 77.8 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.12 [0.41, 3.05] | | < 1 | | 0% | 1 study (1/-) | 41.6 % | NA | not evaluable | | non important | - |
| Gastritis AE (grade 3-4) | 0.51 [0.02, 11.32] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.68 [0.14, 3.38] | | < 1 | | 0% | 1 study (1/-) | 68.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 2.04 [0.13, 32.81] | | < 1 | | 0% | 1 study (1/-) | 30.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.51 [0.02, 11.32] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.02 [0.25, 4.11] | | < 1 | | 0% | 1 study (1/-) | 48.9 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.37 [0.38, 4.89] | | < 1 | | 0% | 1 study (1/-) | 31.6 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.64 [0.27, 1.52] | | < 1 | | 0% | 1 study (1/-) | 84.6 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.63 [0.23, 1.74] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.81 [0.57, 1.14] | | < 1 | | 0% | 1 study (1/-) | 88.8 % | NA | not evaluable | | non important | - |
| Pancytopenia (AE grade 3-4) | 2.05 [0.29, 14.63] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 0.51 [0.02, 11.32] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 1.36 [0.23, 8.21] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.36 [0.23, 8.21] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 1.02 [0.25, 4.11] | | < 1 | | 0% | 1 study (1/-) | 48.9 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 0.72 [0.34, 1.50] | | < 1 | | 0% | 1 study (1/-) | 81.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 4.09 [0.14, 122.39] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 1.02 [0.09, 11.30] | | < 1 | | 0% | 1 study (1/-) | 49.4 % | NA | not evaluable | | non important | - |
| Rash maculopapular AE (grade 3-4) | 1.02 [0.03, 30.50] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 0.14 [0.01, 2.54] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 4.10 [0.37, 45.50] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.67 [0.37, 1.21] | | < 1 | | 0% | 1 study (1/-) | 90.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.78 [0.27, 2.21] | | < 1 | | 0% | 1 study (1/-) | 68.0 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 1.02 [0.09, 11.30] | | < 1 | | 0% | 1 study (1/-) | 49.4 % | NA | not evaluable | | non important | - |
